Trial reportDrug and alcohol dependence2015
Characterizing opioid withdrawal during double-blind buprenorphine detoxification.
Trial report in Drug and alcohol dependence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pharmacological therapies for management of opium withdrawal.The Cochrane database of systematic reviews · 2018Pooled it
- Buprenorphine for managing opioid withdrawal.The Cochrane database of systematic reviews · 2017Pooled it
- The Prescription Opioid Addiction Treatment Study: What have we learned.Drug and alcohol dependence · 2017Trial
- Discontinuing extended-release buprenorphine: Participant experiences from a mixed-methods observational study.Drug and alcohol dependence reports · 2026Article
- Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages.Journal of medical Internet research · 2025Article
- Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.Experimental and clinical psychopharmacology · 2022Article
- Divergent profiles of fentanyl withdrawal and associated pain in mice and rats.Pharmacology, biochemistry, and behavior · 2021Article
- Crosstalk between Sleep Disturbance and Opioid Use Disorder: A Narrative Review.Addiction & health · 2020Review
- Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.The Journal of pharmacology and experimental therapeutics · 2019Review
- Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates.The American journal on addictions · 2019Article
- Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men.Addiction & health · 2018Article
- Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.Drug and alcohol dependence · 2018Article
- Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review.Addiction science & clinical practice · 2016Review
- Self-reported Sleep Improvement in Buprenorphine MAT (Medication Assisted Treatment) Population.Austin journal of drug abuse and addiction · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPrescription opioid (PO) abuse has become an urgent public health issue in the United States. Detoxification is one important treatment option, yet relatively little is known about the time course and severity of opioid withdrawal during buprenorphine detoxification.
methodsThis is a secondary analysis of data from a randomized, placebo-controlled, double-blind evaluation of 1, 2, and 4-week outpatient buprenorphine tapers among primary prescription opioid (PO) abusers. The aim is to characterize the time course and severity of buprenorphine withdrawal under rigorous, double-blind conditions, across multiple taper durations, and using multiple withdrawal-related measures (i.e., self-report and observer ratings, pupil diameter, ancillary medication utilization). Participants were PO-dependent adults undergoing buprenorphine detoxification and biochemically-verified to be continuously abstinent from opioids during their taper (N = 28).
resultsParticipants randomly assigned to the 4-week taper regimen experienced a relatively mild and stable course of withdrawal, with few peaks in severity. In contrast, the 1- and 2-week taper groups experienced stark increases in withdrawal severity during the week following the last buprenorphine dose, followed by declines in withdrawal severity thereafter. The 4-week taper group also reported significantly fewer disruptions in sleep compared to the other experimental groups. When predictors of withdrawal were examined, baseline ratings of "Expected Withdrawal Severity" was the most robust predictor of withdrawal experienced during the taper.
conclusionData from this trial may inform clinicians about the expected time course, magnitude, and pattern of buprenorphine withdrawal and aid efforts to identify patients who may need additional clinical support during outpatient buprenorphine detoxification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.